All Patients, n (%) | Patients With RET-Mutant MTC, n (%) | |||
---|---|---|---|---|
Number of patients, N | 203 | 100.0% | 45 | 100.0% |
Age at advanced diagnosis of MTC | 203 | 100.0% | 45 | 100.0% |
Mean (SD) | 52.2 (10.4) | 46.6 (9.7) | ||
Median (IQR) | 53 (44–59) | 46 (39–54) | ||
Sex | ||||
Female | 119 | 58.6% | 26 | 57.8% |
Male | 84 | 41.4% | 19 | 42.2% |
Race a | ||||
White | 134 | 66.0% | 24 | 53.3% |
Black/African American | 45 | 22.2% | 10 | 22.2% |
Asian, Native Hawaiian or other Pacific Islander | 18 | 8.9% | 6 | 13.3% |
Other b | 1 | 0.5% | 1 | 2.2% |
Unknown or not reported | 6 | 3.0% | 4 | 8.9% |
Ethnic origin | ||||
Hispanic or Latina/Latino | 25 | 12.3% | 5 | 11.1% |
Not Hispanic or Latina/Latino | 163 | 80.3% | 33 | 73.3% |
Unknown or not reported | 15 | 7.4% | 7 | 15.6% |
Total duration of follow-up, months c | 203 | 100.0% | 45 | 100.0% |
Mean (SD) | 24.5 (16.0) | 28.8 (18.0) | ||
Median (IQR) | 21.1 (15.0–28.5) | 25.5 (17.9–34.5) | ||
Clinical stage at initial diagnosis | ||||
Stage II | 10 | 4.9% | 0 | 0.0% |
Stage III | 20 | 9.9% | 6 | 13.3% |
Stage IVA | 58 | 28.6% | 12 | 26.7% |
Stage IVB | 28 | 13.8% | 4 | 8.9% |
Stage IVC | 82 | 40.4% | 22 | 48.9% |
Unknown or not reported | 5 | 2.5% | 1 | 2.2% |
Time from initial diagnosis to advanced diagnosis date (months), among patients who were initially diagnosed with stage I, II, III (n, %) | 30 | 14.8% | 6 | 13.3% |
Mean (SD) | 26.3 (33.0) | 37.5 (64.0) | ||
Median (IQR) | 14.1 (8.2–28.8) | 12.6 (10.1–17) | ||
Site(s) of local extension or metastasis at advanced MTC diagnosis a | 203 | 100% | 25 | 100% |
Distant lymph nodes | 111 | 54.7% | 20 | 44.4% |
Bone | 69 | 34.0% | 18 | 40.0% |
Brain | 14 | 6.9% | 6 | 13.3% |
Liver | 56 | 27.6% | 19 | 42.2% |
Local structures (e.g., muscles, larynx, trachea, esophagus, or large vessels) | 58 | 28.6% | 12 | 26.7% |
Lung/pleura | 81 | 39.9% | 15 | 33.3% |
Performance status at advanced MTC diagnosis (± 30 days) d | 173 | 85.2% | 42 | 93.3% |
0 or 1 | 142 | 82.1% | 36 | 85.7% |
2–4 | 31 | 18.0% | 6 | 14.3% |
Calcitonin level evaluated at advanced MTC diagnosis (± 30 days) (pg/mL) (n, %) e | 141 | 69.5% | 31 | 68.9% |
Calcitonin level known (n, %) | 117 | 83.0% | 23 | 74.2% |
Mean (SD) | 150.1 (138.9) | 139.2 (138.6) | ||
Median (IQR) | 110.0 (22.0–210.0) | 100.0 (18.0–200.0) | ||
Calcitonin evaluated but level unknown or not reported (n, %) | 24 | 17.0% | 8 | 25.8% |
CEA test performed at advanced MTC diagnosis (± 30 days) (ng/mL) (n, %) f | 108 | 53.2% | 26 | 57.8% |
CEA level known (n, %) | 84 | 77.8% | 14 | 53.8% |
Mean (SD) | 30.0 (30.4) | 27.5 (28.2) | ||
Median (IQR) | 18.3 (3.7–50.0) | 19.3 (6.8–30.0) | ||
CEA tested but level unknown or not reported (n, %) | 24 | 22.2% | 12 | 46.2% |